FDA's Letter to Heron Therapeutics (HRTX) Over Sustol Approval
Tweet
Share
E-mailGet Alerts HRTX Hot Sheet
Join SI Premium – FREE
Below is the FDA's approval letter Heron Therapeutics' (Nasdaq: HRTX) SUSTOL:
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BridgeBio reports infigratinib trial data on sleep apnea, ear infections
- Medicure presents Phase 3 PNPO study data at European Epilepsy Congress
- FDA accepts Intellia's lonvo-z application with priority review status
Create E-mail Alert Related Categories
FDA, Insiders' BlogSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
